14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
STLN vs XLO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Xilio Therapeutics, Inc. (XLO) is the stronger overall head-to-head candidate over STLN (STLN) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). STLN carries a Unified Composite Score of 46.6/100 (HOLD) at $3.00 (N/M Forward P/E, N/A operating margin), whereas XLO carries 45.8/100 (HOLD) at $7.56 (N/M Forward P/E, -74.9% operating margin).
Composite vs. Pillar Nuance: While STLN currently prints a higher short-term Unified Composite Score (46.6/100 HOLD vs. XLO 45.8/100 HOLD), XLO captures the overall institutional head-to-head verdict (8–1 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-74.9% vs. N/A operating margin) and revenue trajectory (-47.6% vs. N/A YoY).
Technical & Structure Timing Caution: STLN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.4); meanwhile XLO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on STLN vs XLO. Trailing 12-month operating profitability (STLN N/A vs XLO -74.9%) and valuation multiples (STLN N/M vs XLO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $53.1M market capitalization and -74.9% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ STLN vs XLO Key Questions & Quantitative Answers
As of Nov 20, 2026, Xilio Therapeutics, Inc. (XLO) is the stronger overall head-to-head candidate over STLN (STLN) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). STLN carries a Unified Composite Score of 46.6/100 (HOLD) at $3.00 (N/M Forward P/E, N/A operating margin), whereas XLO carries 45.8/100 (HOLD) at $7.56 (N/M Forward P/E, -74.9% operating margin). Composite vs. Pillar Nuance: While STLN currently prints a higher short-term Unified Composite Score (46.6/100 HOLD vs. XLO 45.8/100 HOLD), XLO captures the overall institutional head-to-head verdict (8–1 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-74.9% vs. N/A operating margin) and revenue trajectory (-47.6% vs. N/A YoY). Technical & Structure Timing Caution: STLN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.4); meanwhile XLO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
XLO leads the Growth & Scale pillar: STLN posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with XLO at -47.6% YoY revenue growth and +0.0% YoY earnings growth on $55M TTM revenue (79.5% gross margin, -74.9% operating margin). On trailing 12-month operating scale, STLN generates N/A in USD-normalized revenue versus $55M for XLO. In operating R&D and SG&A reinvestment, STLN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XLO.
XLO screens cheaper on headline valuation multiples. STLN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas XLO trades at N/M Forward P/E, 11.6x Trailing P/E, N/M PEG, and 1.0x EV/Revenue (-72.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against STLN (N/A ROE) versus XLO (-38.2% ROE) capital efficiency.
In options market volatility and institutional positioning, STLN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.42β · 175% Vol realized risk). By comparison, XLO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.74β · 63% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.